These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 39127065)

  • 1. Imatinib in advanced GIST: if it's working, don't stop a good thing.
    Denu RA; Somaiah N
    Lancet Oncol; 2024 Sep; 25(9):1105-1107. PubMed ID: 39127065
    [No Abstract]   [Full Text] [Related]  

  • 2. Emerging Agents for the Treatment of Advanced, Imatinib-Resistant Gastrointestinal Stromal Tumors: Current Status and Future Directions.
    Bauer S; Joensuu H
    Drugs; 2015 Aug; 75(12):1323-34. PubMed ID: 26187774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retrospective analysis of 85 cases of intermediate-risk gastrointestinal stromal tumor.
    Fu Y; Hao H; Guo L; Yang G; Zhang X
    Oncotarget; 2017 Feb; 8(6):10136-10144. PubMed ID: 28052037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effective Downsizing of a Gastroesophageal GIST Using Neoadjuvant Imatinib Mesylate: a Case Report.
    Asif S; Gupta N; Gupta G; Mehta A; Singh S
    J Gastrointest Cancer; 2017 Jun; 48(2):198-200. PubMed ID: 27006070
    [No Abstract]   [Full Text] [Related]  

  • 5. A Case of Disseminated Intra-abdominal Gastrointestinal Stromal Tumor Managed with Low Dose Imatinib.
    Jang BH; Kim BW; Lim KJ; Kim BG; Park SM; Kim JS; Ji JS; Choi H
    Korean J Gastroenterol; 2015 Jun; 65(6):366-9. PubMed ID: 26087692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imatinib Dosing in Gastrointestinal Stromal Tumors (GISTs): When, How Much, and How Long?
    Milhem M; Deutsch JM
    Curr Clin Pharmacol; 2015; 10(4):311-20. PubMed ID: 26548908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic polymorphisms in angiogenesis-related genes are associated with worse progression-free survival of patients with advanced gastrointestinal stromal tumours treated with imatinib.
    Verboom MC; Kloth JSL; Swen JJ; van der Straaten T; Bovée JVMG; Sleijfer S; Reyners AKL; Mathijssen RHJ; Guchelaar HJ; Steeghs N; Gelderblom H
    Eur J Cancer; 2017 Nov; 86():226-232. PubMed ID: 29054076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The management of metastatic GIST: current standard and investigational therapeutics.
    Kelly CM; Gutierrez Sainz L; Chi P
    J Hematol Oncol; 2021 Jan; 14(1):2. PubMed ID: 33402214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lichenoid drug eruption caused by imatinib mesylate in a Chinese patient with gastrointestinal stromal tumor.
    Luo JR; Xiang XJ; Xiong JP
    Int J Clin Pharmacol Ther; 2016 Sep; 54(9):719-22. PubMed ID: 27345285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ripretinib (Qinlock) for GIST.
    Med Lett Drugs Ther; 2021 Apr; 63(1621):e56-e57. PubMed ID: 33830971
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical efficacy of second-generation tyrosine kinase inhibitors in imatinib-resistant gastrointestinal stromal tumors: a meta-analysis of recent clinical trials.
    Wu L; Zhang Z; Yao H; Liu K; Wen Y; Xiong L
    Drug Des Devel Ther; 2014; 8():2061-7. PubMed ID: 25378911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic therapy of advanced/metastatic gastrointestinal stromal tumors: an update on progress beyond imatinib, sunitinib, and regorafenib.
    Mohammadi M; Gelderblom H
    Expert Opin Investig Drugs; 2021 Feb; 30(2):143-152. PubMed ID: 33252274
    [No Abstract]   [Full Text] [Related]  

  • 13. Systemic therapy options for advanced gastrointestinal stromal tumors beyond first-line imatinib: a systematic review.
    Abdel-Rahman O; Fouad M
    Future Oncol; 2015; 11(12):1829-43. PubMed ID: 26075449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PIK3C2A is a gene-specific target of microRNA-518a-5p in imatinib mesylate-resistant gastrointestinal stromal tumor.
    Shi Y; Gao X; Hu Q; Li X; Xu J; Lu S; Liu Y; Xu C; Jiang D; Lin J; Xue A; Tan Y; Shen K; Hou Y
    Lab Invest; 2016 Jun; 96(6):652-60. PubMed ID: 26950487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of Long-Term Adjuvant Therapy With Imatinib Mesylate After Extensive Surgical Treatment for Ruptured Gastrointestinal Stromal Tumors of the Small Intestine With Peritoneal Metastases: A Case Report.
    Kimura T; Togawa T; Onishi K; Iida A; Sato Y; Goi T
    J Investig Med High Impact Case Rep; 2020; 8():2324709620970736. PubMed ID: 33228387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is there a role of surgery in patients with recurrent or metastatic gastrointestinal stromal tumours responding to imatinib: a prospective randomised trial in China.
    Du CY; Zhou Y; Song C; Wang YP; Jie ZG; He YL; Liang XB; Cao H; Yan ZS; Shi YQ
    Eur J Cancer; 2014 Jul; 50(10):1772-1778. PubMed ID: 24768330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term survival outcome with tyrosine kinase inhibitors and surgical intervention in patients with metastatic or recurrent gastrointestinal stromal tumors: A 14-year, single-center experience.
    Kim JH; Ryu MH; Yoo C; Chae H; Na H; Beck M; Kim BS; Yoo MW; Yook JH; Kim BS; Kim KH; Kim CW; Kang YK
    Cancer Med; 2019 Mar; 8(3):1034-1043. PubMed ID: 30693663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A long-term follow-up of the imatinib mesylate treatment for the patients with recurrent gastrointestinal stromal tumor (GIST): the liver metastasis and the outcome.
    Zhu J; Yang Y; Zhou L; Jiang M; Hou M
    BMC Cancer; 2010 May; 10():199. PubMed ID: 20465813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Management of Unresectable, Advanced Gastrointestinal Stromal Tumours.
    Foo T; Goldstein D; Segelov E; Shapiro J; Pavlakis N; Desai J; Yip D; Zalcberg J; Price TJ; Nagrial A; Chantrill L; Burge M; Karapetis CS; Tebbutt N; Roy AC
    Target Oncol; 2022 Mar; 17(2):95-110. PubMed ID: 35290591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Role of Surgery in Metastatic Gastrointestinal Stromal Tumors.
    Keung EZ; Fairweather M; Raut CP
    Curr Treat Options Oncol; 2016 Feb; 17(2):8. PubMed ID: 26820287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.